 |
12 Companies | 12 Products |
|
|
12 Products | |
0 Diseases | |
115 Trials |  |
7647 News |  |
| «12...9101112131415161718192021 |
- Differences of FENO in adult general populations of Nordic regions (RETIRO) - Aug 26, 2019 - Abstract #ERS2019ERS_5339;
Mean F ENO in asthmatics was 24(19) in Finland, 20(12) in Sweden, and 43(49) in Estonia (p =0.07). Conclusions : We observed a higher mean F ENO in Finland and Sweden compared to Estonia, and found no overall differences of F ENO levels in asthmatics.
- Triple therapy versus dual bronchodilation and long-acting β-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses (8C) - Aug 26, 2019 - Abstract #ERS2019ERS_3447;
- New recommendations and priorities for asthma management (9A) - Aug 26, 2019 - Abstract #ERS2019ERS_2216;
Aims: to provide an update on key changes in the GINA 2019 strategy report, particularly those relating to prevention of exacerbations in mild and severe asthma, and an update on asthma management in children; to highlight current knowledge of the mechanisms underlying the adverse effects of β-agonists in asthma and prevention of exacerbations associated with respiratory viral infections; to identify priority areas for future research and study designs in mild/severe and paediatric asthma. _x000D_
- Part II: Typical cases in primary care with novel insights into management (N103) - Aug 26, 2019 - Abstract #ERS2019ERS_120;
An interactive discussion of the most recent insights into the management of primary care-treated diseases using cases. Aims: to discuss current challenges in primary care management of respiratory diseases; to present how to diagnose and manage sleep apnoea; to address whether interstitial lung disease can be identified earlier; to present what to do regarding short-acting β-agonist use in asthma and what should be said if a patient wants to quit smoking using vapour.
- | venlafaxine / generics
Journal: Dual enantioselective LC-MS/MS method to analyse chiral drugs in surface water: Monitoring in Douro River estuary. (Pubmed Central) - Aug 22, 2019
Venlafaxine (VNF) was found at high concentrations near the affluent of the same tributary river, but its metabolite, O-desmethylvenlafaxine (ODV), was found at concentrations 3 times higher. COC was found every day at all sampling points along the estuary, with slight variations.
- Upregulation of Cardiac Beta 3 -Adrenergic Signaling Promotes Cardiac Aging: Evidence from Chronic Beta 3 -Adrenoceptor Deficiency Mice (120A) - Aug 21, 2019 - Abstract #AHA2019AHA_7536;
Conclusions. Cardiac aging is associated with upregulation of β 3 -AR, which is a critical determinant to the diminished positive modulation of β-adrenergic signaling, and directly contributes to age-associated deficits in LV myocyte functional performance.
- | Journal: Application for Authorization for Therapeutic Use of Beta-Adrenergic Agonists and Inhaled Corticosteroids in Athletes with Asthma. (Pubmed Central) - Aug 11, 2019
Cardiac aging is associated with upregulation of β 3 -AR, which is a critical determinant to the diminished positive modulation of β-adrenergic signaling, and directly contributes to age-associated deficits in LV myocyte functional performance. No abstract available
- | Xolair (omalizumab) / Roche, Novartis
Journal: Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma. (Pubmed Central) - Jul 20, 2019
In practice, the therapeutic programme may change with subsequent notices of the Ministry of Health and does not have to be consistent with the Summary of Product Characteristics for individual preparations. The current review presents the basic principles of differential diagnosis of severe asthma and the selection of the optimal biological therapy in Polish conditions.
- | Clinical, Journal: Factors affecting the choice of therapeutic regimens in asthma and chronic obstructive pulmonary disease patients and patient adherence to the therapies prescribed. (Pubmed Central) - Jul 20, 2019
The most common treatments for asthma and COPD in Poland are inhaled glucocorticosteroids and long-acting β agonists. The main factors influencing treatment decisions are the current GINA and GOLD recommendations as well as patients' age, comorbidities, and price of treatment.
- | Clinical, Journal: Efficacy of ciclesonide in the treatment of patients with asthma exacerbation. (Pubmed Central) - Jul 20, 2019
Treatment options containing ciclesonide have shown statistically and clinically important advantages (improvement of Asthma Control Test score, reduction in rescue medication consumption, reduction in day and night symptoms score, improvement in spirometry parameters, decrease in exhaled nitric oxide, and no necessity of oral corticosteroids treatment) in comparison to patients for whom medium doses of the previously used inhaled corticosteroid were doubled. Treating with high doses of ciclesonide is characterised by a quick and potent anti-inflammatory effect as well as prompt clinical improvement along with the proper safety profile in patients experiencing asthma exacerbations.
- | Simdax (levosimendan IV) / AbbVie
Journal: Sepsis-induced myocardial dysfunction. (Pubmed Central) - Jun 20, 2019
Significant strides have been made in understanding the intramyocardial inflammatory response that causes myocardial dysfunction. A number of novel approaches show promise by modulating the intramyocardial inflammatory response.
- | Journal: Regulatory effect of decreasing therapeutic duplication of respiratory drugs using a prescription database between 2012 and 2015. (Pubmed Central) - May 22, 2019
TD by a different prescriber decreased only for xanthine bronchodilators, but increased more than 10% for beta-receptor agonists (+27.07, +1.42), leukotriene receptor antagonists (+16.10, +0.44), cough suppressants (+15.64, +0.52), mucolytic agents (+11.16, +0.67). The 2013 regulation regarding respiratory drugs did not have the anticipated effect of reducing TD prevalence; more effective interventions are needed.
- | Journal: Therapeutic strategies against cancer cachexia. (Pubmed Central) - Apr 27, 2019
The multi-targeted approach seems essential in these treatments, which should include the combination of both nutritional support, drugs and a suitable program of physical exercise, in order to ameliorate both anorexia and the metabolic changes associated with cachexia. In addition, another very important and crucial aspect to be taken into consideration in the design of clinical trials for the treatment of cancer cachexia is to staging cancer patients in relation with the degree of cachexia, in order to start as early as possible this triple approach in the course of the disease, even before the weight loss can be detected.
- | Journal: Exogenous Cytokine-Free Differentiation of Human Pluripotent Stem Cells into Classical Brown Adipocytes. (Pubmed Central) - Apr 27, 2019
Indeed, we have found that BA produces an unknown small (<1000 Da), highly hydrophilic molecule that augments insulin secretion from pancreatic beta cells. Our upgraded technique will contribute to an advancement of stem cell study for diverse purposes.
- | Journal: The beta-adrenergic receptor agonist, terbutaline, reduces UVB-induced mechanical sensitization in humans. (Pubmed Central) - Apr 19, 2019
Our upgraded technique will contribute to an advancement of stem cell study for diverse purposes. Similar to our cellular observations, also in humans beta-adrenergic agonists such as terbutaline can reduce the sensitization of primary neurons in the skin.
- | Xolair (omalizumab) / Roche, Novartis
Journal: Variability in total serum IgE over 1Â year in severe asthmatics. (Pubmed Central) - Apr 13, 2019
Immunoglobulin E (IgE) is the treatment target of omalizumab, a monoclonal antibody indicated in the treatment of severe allergic asthma...sIgE decreases with age. Variation in sIgE weakly associates with asthma control but not with exacerbation.
- | Preclinical, Journal: Isoproterenol-Induced Heart Failure Mouse Model Using Osmotic Pump Implantation. (Pubmed Central) - Mar 29, 2019
The success of model creation may be assessed by echocardiogram or molecular markers. This chapter may be relevant to those who are interested in using this heart failure model.